Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial

被引：12
|
作者：
Le Morvan, V. [1 ]
Litiere, S. [2 ]
Laroche-Clary, A. [1 ]
Ait-Ouferoukh, S. [1 ]
Bellott, R. [1 ]
Messina, C. [2 ]
Cameron, D. [3 ]
Bonnefoi, H. [1 ]
Robert, J. [1 ]
机构：
[1] Univ Bordeaux Segalen, INSERM, U916, Inst Bergonie, F-33076 Bordeaux, France
[2] EORTC, Brussels, Belgium
[3] Univ Edinburgh, Edinburgh, Midlothian, Scotland
来源：
PHARMACOGENOMICS JOURNAL | 2015年 / 15卷 / 01期
关键词：
EORTC; 10994/BIG; 1-00; GENETIC POLYMORPHISMS; ANTICANCER DRUG; ALCOHOL-DEHYDROGENASE; CELL-LINES; P53; SUSCEPTIBILITY; RISK; MDM2; CONTRIBUTES;
D O I：
10.1038/tpj.2014.24
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Using cell line panels we identified associations between single-nucleotide polymorphisms (SNPs) and chemosensitivity. To validate these findings in clinics, we genotyped a subset of patients included in a neoadjuvant breast cancer trial to explore the relationship between genotypes and clinical outcome according to treatment received and p53 status. We genotyped 384 selected SNPs in the germline DNA extracted from formalin-fixed paraffin-embedded non-invaded lymph nodes of 243 patients. The polymorphisms of five selected genes were first studied, and then all 384 SNPs were considered. Correction for multiple testing was applied. CYP1B1 polymorphism was significantly associated with pathological complete response (pCR) in patients who had received DNA-damaging agents. MDM2, MDM4 and TP53BP1 polymorphisms were significantly associated with pCR in patients harboring a p53-positive tumor. In the complete SNP panel, there was a significant association between overall survival (OS) and a SNP of ADH1C, R272Q (P = 0.0023). By multivariate analysis, only ADH1C genotype and p53 status were significantly associated with OS.
引用
收藏
页码：63 / 68
页数：6
相关论文
共 50 条
  • [31] Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
    de Groot, S.
    Janssen, L. G. M.
    Charehbili, A.
    Dijkgraaf, E. M.
    Smit, V. T. H. B. M.
    Kessels, L. W.
    van Bochove, A.
    van Laarhoven, H. W. M.
    Kranenbarg, E. Meershoek-Klein
    van Leeuwen-Stok, A. E.
    van de Velde, C. J. H.
    Putter, H.
    Nortier, J. W. R.
    van der Hoeven, J. J. M.
    Pijl, H.
    Kroep, J. R.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (02) : 461 - 466
  • [32] Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial
    Gonzalez-Rivera, Milagros
    Lobo, Miriam
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    del Monte-Millan, Maria
    Massarrah, Tatiana
    Ramos-Medina, Rocio
    Ocana, Inmaculada
    Picornell, Antoni
    Santillan Garzon, Sonia
    Perez-Carbornero, Lucia
    Garcia-Saenz, Jose A.
    Gomez, Henry
    Moreno, Fernando
    Marquez-Rodas, Ivan
    Fuentes, Hugo
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (03) : 507 - 515
  • [33] Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
    Kimbung, Siker
    Markholm, Ida
    Bjohle, Judith
    Lekberg, Tobias
    von Wachenfeldt, Anna
    Azavedo, Edward
    Saracco, Ariel
    Hellstrom, Mats
    Veerla, Srinivas
    Paquet, Eric
    Bendahl, Par-Ola
    Ferno, Marten
    Bergh, Jonas
    Loman, Niklas
    Hatschek, Thomas
    Hedenfalk, Ingrid
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (03) : 618 - 628
  • [34] Serum Enzymes and Pathologic Complete Response to the Addition of Targeted Therapy in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer Patients
    Chen, Zongshun
    Zhang, Jing
    Chen, Wei
    Chen, Xueyi
    Lu, Da-Lin
    Li, Junjie
    ANNALS OF SURGICAL ONCOLOGY, 2025, : 4008 - 4016
  • [35] Treatment Efficacy Scored-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
    Marczyk, M.
    Mrukwa, A.
    Yau, C.
    Wolf, D.
    Chen, Y-Y
    Balassanian, R.
    Nanda, R.
    Parker, B. A.
    Krings, G.
    Sattar, H.
    Zeck, J. C.
    Albain, K. S.
    Boughey, J. C.
    Liu, M. C.
    Elias, A. D.
    Clark, A. S.
    Venters, S. J.
    Shad, S.
    Basu, A.
    Asare, S. M.
    Buxton, M.
    Asare, A. L.
    Rugo, H. S.
    Perlmutter, J.
    DeMichele, A. M.
    Yee, D.
    Berry, D. A.
    van't Veer, L.
    Symmans, W. F.
    Esserman, L.
    Pusztai, L.
    ANNALS OF ONCOLOGY, 2022, 33 (08) : 814 - 823
  • [36] Real-time exercise reduces impaired cardiac function in breast cancer patients undergoing chemotherapy: A randomized controlled trial
    Chung, Wei-Pang
    Yang, Hsin-Lun
    Hsu, Ya-Ting
    Hung, Ching-Hsia
    Liu, Ping-Yen
    Liu, Yen-Wen
    Chan, Shih-Hung
    Tsai, Kun-Ling
    ANNALS OF PHYSICAL AND REHABILITATION MEDICINE, 2022, 65 (02)
  • [37] Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II-III breast cancer patients treated with neoadjuvant chemotherapy
    Koolen, Bas B.
    Olmos, Renato A. Valdes
    Vogel, Wouter V.
    Peeters, Marie Jeanne T. F. D. Vrancken
    Rodenhuis, Sjoerd
    Rutgers, Emiel J. Th.
    Elkhuizen, Paula H. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 141 (02) : 249 - 254
  • [38] Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response
    Lejeune, Marylene
    Reverte, Laia
    Sauras, Esther
    Gallardo, Noelia
    Bosch, Ramon
    Roso, Albert
    Petit, Anna
    Peg, Vicente
    Riu, Francisco
    Garcia-Fontgivell, Joan
    Ibanez, Jose
    Relea, Fernanda
    Vieites, Begona
    Bor, Catherine
    de la Cruz-Merino, Luis
    Arenas, Meritxell
    Rodriguez, Valerie
    Galera, Juana
    Korzynska, Anna
    Belhomme, Philippe
    Plancoulaine, Benoit
    alvaro, Tomas
    Lopez, Carlos
    CANCERS, 2023, 15 (03)
  • [39] Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer
    Koenig, Lisa
    Mairinger, Fabian D.
    Hoffmann, Oliver
    Bittner, Ann-Kathrin
    Schmid, Kurt W.
    Kimmig, Rainer
    Kasimir-Bauer, Sabine
    Bankfalvi, Agnes
    BMC CANCER, 2019, 19 (1)
  • [40] Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: Identification rate and nodal outcome
    Donker, Mila
    Straver, Marieke E.
    van Tienhoven, Geertjan
    van de Velde, Cornelis J. H.
    Mansel, Robert E.
    Litiere, Saskia
    Werutsky, Gustavo
    Duez, Nicole J.
    Orzalesi, Lorenzo
    Bouma, Willem H.
    van der Mijle, Huub
    Nieuwenhuijzen, Grard A. P.
    Veltkamp, Sanne C.
    Westenberg, A. Helen
    Rutgers, Emiel J. T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (09) : 2093 - 2100
12345